Stocktoria

Scilex Holding Co SCLX

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-11 · LEI

Scilex Holding Co financials (annual)

Revenue
$23.6M $31.3M $38.0M $46.7M $56.6M $30.3M 202020212022202320242025
Net income
-$47.5M -$88.4M -$23.4M -$114.3M -$72.8M -$374.1M 202020212022202320242025
Free cash flow
-$31.5M -$28.7M $21.3M -$20.7M $19.3M $3.7M 202020212022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020
Revenue$30.3M$56.6M$46.7M$38.0M$31.3M$23.6M
R&D expense$20.7M$9.6M$12.7M$9.1M$9.2M$10.0M
SG&A expense$266.9M$119.0M$119.6M$64.9M$50.6M$43.0M
Operating income-$346.0M-$83.4M-$105.4M-$50.6M-$35.8M-$35.3M
Interest expense$1.1M$9.6M$11.8M$13.1M
Income tax$26,000-$1,000$13,000$4,000$5,000-$53,000
Net income-$374.1M-$72.8M-$114.3M-$23.4M-$88.4M-$47.5M
EPS (diluted)$-36.48$-8.05$-1.28$-0.17$-0.67$-0.36
Operating cash flow$3.8M$19.3M-$20.7M$21.3M-$28.7M-$31.5M
Free cash flow$3.7M$19.3M-$20.7M$21.3M-$28.7M-$31.5M
Cash & equivalents$5.0M$3.3M$3.9M$2.2M$4.3M$30,511
Inventory$4.8M$2.4M$4.2M$1.4M$2.6M
Total assets$365.0M$93.0M$101.3M$86.5M$77.9M$199,484
Total liabilities$576.7M$285.6M$274.2M$50.3M$301.8M$180,760
Shareholders' equity-$211.8M-$192.6M-$172.9M$36.2M-$223.9M-$141.7M

Growth · year-over-year · Revenue CAGR 5.1%

MetricFY2025FY2024FY2023FY2022FY2021FY2020
Revenue growth-46.5%+21.1%+22.9%+21.4%+32.9%
Free cash flow growth-81.0%-197.4%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.